George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2
12 juil. 2023 07h00 HE
|
George Medicines
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled in active-controlled trial...
George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial
07 sept. 2022 03h00 HE
|
George Medicines
George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial Novel proprietary low-dose, single-pill triple combination, GMRx2, is in late-stage...
George Medicines advances triple combination candidate GMRx4 into Phase II clinical development for first-line treatment of type 2 diabetes
20 juil. 2022 07h00 HE
|
George Medicines
George Medicines advances triple combination candidate GMRx4 into Phase II clinical development for first-line treatment of type 2 diabetes GMRx4 is the second candidate to be prioritised in...
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
17 janv. 2022 07h00 HE
|
George Medicines
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill 500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to...
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
17 janv. 2022 02h00 HE
|
George Medicines
Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill 500 UK patients to be treated as part of global trial Investigational single-pill combination offers potential to...
George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director
12 juil. 2021 07h00 HE
|
George Medicines
George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on providing innovative and...
George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director
12 juil. 2021 02h00 HE
|
George Medicines
George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director London, UK, 12 July 2021 – George Medicines, a late-stage drug development company focused on providing innovative and...
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension
01 juil. 2021 07h00 HE
|
George Medicines
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood...
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension
01 juil. 2021 02h00 HE
|
George Medicines
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood...
George Medicines appoints Stefan König as Chief Executive Officer
03 juin 2021 07h00 HE
|
George Medicines
George Medicines appoints Stefan König as Chief Executive Officer Mr König joins to lead late-stage drug development company developing proprietary fixed dose combination therapies for...